Skip to content
Evigrade
CriticalSelective If channel inhibitor of the sinoatrial node×HIV protease inhibitor / pharmacokinetic booster

Updated · Methodology

Mechanism

In the liver and gut, only the enzyme CYP3A4 breaks down ivabradine. The strong inhibitors ketoconazole and josamycin raised mean ivabradine exposure 7- to 8-fold, and high ivabradine levels can cause excessive slowing of the heart rate (ivabradine summary of product characteristics, SmPC, European Medicines Agency, EMA). Ritonavir strongly inhibits CYP3A enzymes, and even the low doses used to boost other antiviral drugs have marked effects on the pharmacokinetics of drugs metabolised by CYP3A4 (ritonavir SmPC, EMA). The documents do not say how much ritonavir raises ivabradine levels. The nirmatrelvir/ritonavir documents attribute the contraindication to the risk of bradycardia and conduction disturbances (nirmatrelvir/ritonavir SmPC, EMA, and label, US Food and Drug Administration, FDA). Ritonavir itself prolongs the PR interval on the electrocardiogram in some people. Second- or third-degree atrioventricular block has rarely been reported in people with structural heart disease or pre-existing conduction abnormalities, or in those taking drugs that prolong the PR interval (ritonavir SmPC, EMA, and FDA label). First-degree atrioventricular block with PR prolongation is a common adverse reaction of ivabradine (ivabradine SmPC, EMA).

Symptoms

Excess ivabradine causes severe and prolonged slowing of the heart rate: a resting heart rate below 50 beats per minute, dizziness, fatigue and low blood pressure (ivabradine summary of product characteristics, SmPC, European Medicines Agency, EMA). Sinus arrest and heart block have also occurred during ivabradine treatment (ivabradine label, US Food and Drug Administration, FDA). Ritonavir can change the electrocardiogram (ECG), for example by prolonging the PR interval, and conduction problems may cause dizziness, lightheadedness, an abnormal heart rhythm or loss of consciousness (ritonavir FDA label). A slow heart rate may increase the risk of QT prolongation and severe ventricular arrhythmias, including torsade de pointes, especially in people taking QT-prolonging drugs (ivabradine FDA label).

Management

The combination is contraindicated. The European ivabradine summary of product characteristics (SmPC) lists ritonavir among the strong inhibitors of the enzyme CYP3A4 that must not be taken with ivabradine (ivabradine SmPC, European Medicines Agency, EMA). The US label contraindicates all strong CYP3A4 inhibitors, giving human immunodeficiency virus (HIV) protease inhibitors as an example (ivabradine label, US Food and Drug Administration, FDA). On the ritonavir side, the documents for nirmatrelvir/ritonavir, a COVID-19 treatment, explicitly contraindicate ivabradine (nirmatrelvir/ritonavir SmPC, EMA, and FDA label). The ritonavir tablet documents do not name ivabradine but describe ritonavir as a strong CYP3A inhibitor (ritonavir SmPC, EMA, and FDA label). The contraindication has no dose condition, so it also applies to the low doses of ritonavir used to boost other antiviral drugs (this follows from the contraindication in the ivabradine SmPC, EMA). Do not use ivabradine with a long-term antiviral regimen containing ritonavir, and pause it during a 5-day course of nirmatrelvir/ritonavir (this follows from the contraindication). The documents give no interval for restarting ivabradine after the last dose of ritonavir. Use ritonavir with caution in heart disease and pre-existing conduction abnormalities, and combine it with other drugs that prolong the PR interval with caution and clinical monitoring (ritonavir SmPC, EMA, and FDA label). If the drugs have already been taken together, stop one of them (this follows from the contraindication) and monitor the heart rate and electrocardiogram (ECG). With a resting heart rate below 50 beats per minute or symptoms of bradycardia, reduce the ivabradine dose, and if bradycardia persists, stop ivabradine (ivabradine SmPC, EMA). Treat severe bradycardia in a specialised setting: if it is poorly tolerated, consider intravenous beta-stimulants such as isoprenaline and, if needed, temporary cardiac pacing (ivabradine SmPC, EMA). The US label also mentions intravenous fluids and atropine (ivabradine FDA label).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Ivabradine

Other interactions with Ritonavir